Physician profile
Daniel R Field
NPI 1922485531
$3,390.42
in general payments reported to CMS, 2019-2025
25 companies · $269 in 2025
The $269 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $240 · 2021: $186 · 2022: $189 · 2023: $363 · 2024: $255 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $434.96 | 2019-2020 | |
| Pfizer INC. | $338.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $325.74 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.77 | 2019-2021 | |
| Lilly USA, LLC | $296.43 | 2019-2021 | |
| Novo Nordisk INC | $280.89 | 2019-2025 | Ozempic |
| Dexcom, INC. | $250.65 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $235.62 | 2019-2021 | |
| Astellas Pharma US INC | $161.70 | 2020-2024 | Veozah, Myrbetriq |
| Alexion Pharmaceuticals, INC. | $115.02 | 2019-2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $108.38 | 2019-2023 | Xarelto |
| Abbvie INC. | $107.02 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $73.96 | 2019-2020 | |
| Gilead Sciences, INC. | $61.67 | 2021-2025 | Veklury |
| Mallinckrodt Enterprises LLC | $55.63 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.99 | 2019-2025 | Xifaxan |
| Vifor Pharma, INC. | $34.37 | 2019-2020 | |
| Genzyme Corporation | $31.24 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $22.98 | 2025 | |
| Dermira, INC. | $21.45 | 2019 | |
| Medtronic, INC. | $20.84 | 2023 | Minimed 780g |
| Amicus Therapeutics, INC. | $18.74 | 2020 | |
| Bridgebio Pharma, INC. | $18.21 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $16.38 | 2024 | |
| Merck Sharp & Dohme LLC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.